.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,776,895

« Back to Dashboard

Claims for Patent: 7,776,895

Title:Inhalation devices for delivering phenethanolamine derivatives for the treatment of respiratory diseases
Abstract: The invention provides inhalation devices comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl)phenol; or a salt or solvate thereof, inhalation devices comprising formulations and combinations of the compound or a salt or solvate thereof, and methods for the treatment or prophylaxis of a clinical condition in a mammal by employing the inhalation devices.
Inventor(s): Box; Philip Charles (Stevenage, GB), Coe; Diane Mary (Stevenage, GB), Looker; Brian Edgar (Stevenage, GB), Mann; Inderjit Singh (Stevenage, GB), Procopiou; Panayiotis Alexandrou (Stevenage, GB)
Assignee: Glaxo Group Limited (Greenford, Middlesex, GB)
Application Number:12/211,322
Patent Claims: 1. An inhaler for delivering a pharmaceutically active compound to the lung, said inhaler comprising one or more containers having a dry powder formulation present therein, said dry powder formulation comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl)oxy]ethoxy}hexyl)amino]-1-hydroxyet- hyl}-2-(hydroxymethyl) phenol; or a pharmaceutically acceptable salt thereof.

2. An inhaler according to claim 1, wherein the compound is present as a pharmaceutically acceptable salt which is a .alpha.-phenyl cinnamate salt.

3. An inhaler according to claim 1, wherein the compound is present as a pharmaceutically acceptable salt which is a 1-naphthoate salt.

4. An inhaler according to claim 1, wherein the compound is present as a pharmaceutically acceptable salt which is an (R)-mandelate salt.

5. An inhaler according to claim 1, wherein the compound is present in particles ranging in size from 1 .mu.m to 10 .mu.m.

6. An inhaler according to claim 1, wherein the dry powder formulation comprises lactose.

7. An inhaler for delivering a pharmaceutically active compound to the lung, said inhaler comprising one or more containers having a dry powder formulation present therein, said dry powder formulation comprising a compound which is 4-{(1R)-2-[(6-{2-[(2,6-dichlorobenzyl) oxy]ethoxy}hexyl)amino]-1-hydroxyethyl}-2-(hydroxymethyl)phenol-triphenyl acetate.

8. An inhaler according to claim 7, wherein the compound is present in particles ranging in size from 1 .mu.m to 10 .mu.m.

9. An inhaler according to claim 7, wherein the dry powder formulation comprises lactose.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc